AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2893314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intraventricular bethanechol (1.75 mg/d)
Number of subjects: 10
Study 2893314 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 29429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity‐modulated radiotherapy (IMRT) with concurrent platinum‐based chemotherapy (CCRT group, n = 27)
Number of subjects: 91
Study 29429800 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical surgery with or without adjuvant treatment (NACT group, n = 39)
Number of subjects: 91
Study 29429800 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery with or without adjuvant treatment (RH group, n = 25)
Number of subjects: 91
Study 28320368 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (6-min videoclip explaining diagnosis and surgery options)
Number of subjects: 80
Study 28320368 — intervention group
Group type: COMPARATOR
Intervention: Regular information only (Control)
Number of subjects: 80
Study 25474194 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructive surgery
Number of subjects: 120
Study 25474194 — intervention group
Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 120
Study 25474194 — intervention group
Group type: COMPARATOR
Intervention: Facial lesions
Number of subjects: 120
Study 23343386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity (three 50-minute sessions/week over 10 weeks)
Number of subjects: 138
Study 23343386 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Program (2.5-hours per week over 6 weeks)
Number of subjects: 138
Study 23343386 — intervention group
Group type: COMPARATOR
Intervention: Health Guidance (1.5-hour individualised dialogue)
Number of subjects: 138
Study 23343386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Number of subjects: 138
Study 23343386 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Program
Number of subjects: 138
Study 23343386 — intervention group
Group type: COMPARATOR
Intervention: Health Guidance
Number of subjects: 138
Study 21640689 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 14
Study 21640689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18975316 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for DM2 in patients diagnosed with FM
Number of subjects: 63
Study 18975316 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 63
Study 16816554 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 400 mg/day
Number of subjects: 50
Study 16816554 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 800 mg/day
Number of subjects: 50
Study 16816554 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 1200 mg/day
Number of subjects: 50
Study 16816554 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 1600 mg/day
Number of subjects: 50
Study 16816554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12601207 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 34
Study 12601207 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial angiography (control)
Number of subjects: 34
Study 10567286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary autograft
Number of subjects: 47
Study 10567286 — intervention group
Group type: COMPARATOR
Intervention: Aortic homograft
Number of subjects: 47
Study 10567286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 8916239 — intervention group
Group type: EXPERIMENTAL
Intervention: Program with employment specialist
Number of subjects: 122
Study 8916239 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specialized vocational services
Number of subjects: 122
Study 1919633 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN gamma) at 10, 50, or 100 micrograms/m2 plus tumor necrosis factor-alfa (TNF alpha) at 10, 50, or 100 micrograms/m2 every other day for 20 days (10 doses)
Number of subjects: 0
Study 1919633 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of 100 micrograms/m2 IFN gamma and 50 micrograms/m2 TNF alpha every other day (maximally tolerated dose)
Number of subjects: 0
Study 6925851 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program with high indirect interventions
Number of subjects: 160
Study 6925851 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphasis on negative consequences of uncontrolled hypertension
Number of subjects: 160
Study 6925851 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional meetings and emphasis on patient responsibility (combined)
Number of subjects: 160
Study 6925851 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (overall)
Number of subjects: 160
Study 31486777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency MST (100 Hz)
Number of subjects: 86
Study 31486777 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-frequency MST (60 or 50 Hz)
Number of subjects: 86
Study 31486777 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency MST (25 Hz)
Number of subjects: 86
Study 31486777 — intervention group
Group type: EXPERIMENTAL
Intervention: MST (overall)
Number of subjects: 86
Study 31441409 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu group (received 60 mL Shenfu injection infusion for 7 days)
Number of subjects: 50
Study 31441409 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu group
Number of subjects: 50
Study 28585750 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy (30 mL kg‐1 h‐1 infusion of Ringer's lactate solution)
Number of subjects: 150
Study 28585750 — intervention group
Group type: COMPARATOR
Intervention: Restricted fluid therapy (10 mL kg‐1 h‐1 infusion of Ringer's lactate solution)
Number of subjects: 150
Study 28585750 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy
Number of subjects: 150
Study 28585750 — intervention group
Group type: COMPARATOR
Intervention: Restricted fluid therapy
Number of subjects: 150
Study 26645521 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS2) 10 g/d for 8 weeks
Number of subjects: 60
Study 26645521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23178539 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation (heat pain 46-47°C/cold pain 2-3°C) 3 days/week for 8 weeks
Number of subjects: 34
Study 23178539 — intervention group
Group type: COMPARATOR
Intervention: Innocuous thermal stimulation (heat 40-41°C/cold 23-24°C) 3 days/week for 8 weeks
Number of subjects: 34
Study 23178539 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation
Number of subjects: 34
Study 21465247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.3 g kg(‐1) body weight)
Number of subjects: 10
Study 21465247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18077465 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 33
Study 16503887 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketanserin ointment
Number of subjects: 12
Study 16503887 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated vehicle (placebo)
Number of subjects: 12
Study 12776029 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG with the introducer method (Group I)
Number of subjects: 58
Study 12776029 — intervention group
Group type: COMPARATOR
Intervention: PEG with the pull method (Group II)
Number of subjects: 58
Study 10884197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup with cluster holes for adjunctive screw fixation (n = 30)
Number of subjects: 62
Study 10884197 — intervention group
Group type: COMPARATOR
Intervention: Cup without holes (n = 34)
Number of subjects: 62
Study 10884197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 9231316 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 26
Study 9231316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1524744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed resin composite restoration (CompS/C)
Number of subjects: 0
Study 1524744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-conservative sealed amalgam restorations (AGS)
Number of subjects: 0
Study 1524744 — intervention group
Group type: COMPARATOR
Intervention: Traditional unsealed amalgam restorations (AGU)
Number of subjects: 0
Study 1524744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed amalgam restorations (AGS)
Number of subjects: 0
Study 6344379 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 27
Study 6344379 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 27
Study 3532242 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological training of stress management, relaxation, and self-control techniques for 13 type A post-MI patients over a 4-8 week inpatient rehabilitation programme.
Number of subjects: 91
Study 3532242 — intervention group
Group type: COMPARATOR
Intervention: Control group KG (A) - 23 type A post-MI patients who did not receive psychological training.
Number of subjects: 91
Study 3532242 — intervention group
Group type: COMPARATOR
Intervention: Control group KG (B) - 20 type A smoker counselling clients who did not receive psychological training.
Number of subjects: 91
Study 28315922 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined femoral-obturator-sciatic nerve block (FOS Group)
Number of subjects: 0
Study 28315922 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar plexus block and sciatic nerve block (PLPS Group)
Number of subjects: 0
Study 27474357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan iontophoretic transdermal system (TDS) for 4 hours
Number of subjects: 37
Study 23059481 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with 2 permanent and 2 releasable sutures (R group)
Number of subjects: 175
Study 23059481 — intervention group
Group type: COMPARATOR
Intervention: Standard trabeculectomy (S group)
Number of subjects: 175
Study 23059481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 175
Study 22434537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 103
Study 22434537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 21122658 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly measured low-density lipoprotein cholesterol (D-LDL-C)
Number of subjects: 81
Study 21122658 — intervention group
Group type: COMPARATOR
Intervention: Calculated low-density lipoprotein cholesterol (C-LDL-C)
Number of subjects: 81
Study 18640794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (20% concentration)
Number of subjects: 32
Study 18640794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% concentration)
Number of subjects: 32
Study 18640794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (40% concentration)
Number of subjects: 32
Study 18640794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100% oxygen)
Number of subjects: 32
Study 16417773 — intervention group
Group type: EXPERIMENTAL
Intervention: Penyanqing Capsule (PYQC), 3 times a day, 4 capsules each time, for 2 months
Number of subjects: 82
Study 16417773 — intervention group
Group type: COMPARATOR
Intervention: Fuyankang tablets (FYKT), 3 times a day, 6 tablets each time, for 2 months
Number of subjects: 82
Study 16417773 — intervention group
Group type: EXPERIMENTAL
Intervention: Penyanqing Capsule (PYQC)
Number of subjects: 82
Study 12847648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lösferron (ferrous gluconate, Lilly Pharma, Hamburg) - 0.5 l
Number of subjects: 52
Study 12847648 — intervention group
Group type: COMPARATOR
Intervention: No oral contrast agent
Number of subjects: 52
Study 10561318 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+) tumor-infiltrating lymphocytes (TILs) plus low-dose recombinant interleukin-2 (rIL-2)
Number of subjects: 178
Study 10561318 — intervention group
Group type: COMPARATOR
Intervention: Placebo cell infusion plus low-dose recombinant interleukin-2 (rIL-2)
Number of subjects: 178
Study 8759178 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.90 IU/kg/week (D2)
Number of subjects: 97
Study 8759178 — intervention group
Group type: COMPARATOR
Intervention: 0.45 IU/kg/week (D1)
Number of subjects: 97
Study 8759178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 1762973 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music (preference of seven types)
Number of subjects: 15
Study 1762973 — intervention group
Group type: COMPARATOR
Intervention: Control (60-cycle hum)
Number of subjects: 15
Study 7110301 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care treatment
Number of subjects: 7825
Study 7110301 — intervention group
Group type: COMPARATOR
Intervention: Referred care
Number of subjects: 7825
Study 30121121 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement
Number of subjects: 111
Study 30121121 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence
Number of subjects: 111
Study 30121121 — intervention group
Group type: COMPARATOR
Intervention: Parental absence
Number of subjects: 111
Study 29655624 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine immunizations (DTwP-HepB-Hib, oral polio, pneumococcal conjugate 7 vaccines)
Number of subjects: 212
Study 27189657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mL/kg dose of 10% fluorescein sodium
Number of subjects: 0
Study 27189657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mL/kg dose of 10% fluorescein sodium
Number of subjects: 0
Study 27189657 — intervention group
Group type: EXPERIMENTAL
Intervention: pCLE
Number of subjects: 0
Study 25322766 — intervention group
Group type: COMPARATOR
Intervention: Regular NHGDoc decision support modules
Number of subjects: 120
Study 25322766 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular NHGDoc decision support modules plus an additional module on heart failure
Number of subjects: 120
Study 22708649 — intervention group
Group type: EXPERIMENTAL
Intervention: TBV 600 mg BID monotherapy for 4 weeks followed by combination therapy with PIFN (pre-dosing arm)
Number of subjects: 42
Study 22708649 — intervention group
Group type: COMPARATOR
Intervention: TBV administered concurrently with PIFN (standard dosing arm)
Number of subjects: 42
Study 20063435 — intervention group
Group type: EXPERIMENTAL
Intervention: S90049 (60 mg)
Number of subjects: 30
Study 20063435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20063435 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 30
Study 17387129 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus 60 mg of torcetrapib daily
Number of subjects: 1188
Study 17387129 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 1188
Study 16139703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflated on straight leg
Number of subjects: 100
Study 16139703 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet inflated on maximally flexed knee
Number of subjects: 100
Study 16139703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet deflation
Number of subjects: 100
Study 11694947 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant urate oxidase
Number of subjects: 183
Study 11694947 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 183
Study 9415234 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolaevulinic acid photodynamic therapy
Number of subjects: 22
Study 7894919 — intervention group
Group type: COMPARATOR
Intervention: Regional nerve block (RNB) with stellate ganglion block and suprascapular nerve block by 1% xylocaine 10 ml
Number of subjects: 150
Study 7894919 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EAP) with local acupoints: Chien‐Yu, Chien‐Ching, Chien‐Nei‐Ling, Ah‐Shih Hsueh
Number of subjects: 150
Study 7894919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EAP + RNB
Number of subjects: 150
Study 2440351 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (mean dose 4.3 +/- 0.2 mg/kg)
Number of subjects: 60
Study 2440351 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.6 +/- 0.02 mg/kg)
Number of subjects: 60
Study 2440351 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (7 +/- 0.4 micrograms/kg)
Number of subjects: 60
Study 2440351 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (1.3 +/- 0.1 microgram/kg)
Number of subjects: 60
Study 30453076 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas Primary Care
Number of subjects: 456
Study 30453076 — intervention group
Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 456
Study 28205185 — intervention group
Group type: EXPERIMENTAL
Intervention: OPERA dietary supplement (alpha-lipoic acid, Boswellia Serrata, methylsulfonylmethane, and bromelain)
Number of subjects: 25
Study 28205185 — intervention group
Group type: EXPERIMENTAL
Intervention: OPERA dietary supplement
Number of subjects: 25
Study 25812128 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Test (PASAT) administered to patients with MS
Number of subjects: 100
Study 25812128 — intervention group
Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Test (PASAT) administered to normal controls
Number of subjects: 100
Study 23669304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate-antacid (Gaviscon Double Action Liquid)
Number of subjects: 16
Study 23669304 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Antagel)
Number of subjects: 16
Study 21884858 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Medical Services (EMS) transport
Number of subjects: 263
Study 21884858 — intervention group
Group type: COMPARATOR
Intervention: Self-presenting patients
Number of subjects: 263
Study 19114704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg every 2 weeks
Number of subjects: 48
Study 19114704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan at progression
Number of subjects: 48
Study 16955187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inosiplex (50 mg/kg/day in five divided doses for 12 weeks)
Number of subjects: 32
Study 16955187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15113819 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 1237
Study 15113819 — intervention group
Group type: COMPARATOR
Intervention: Calcium or placebo (control)
Number of subjects: 1237
Study 15113819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis with additional studies
Number of subjects: 1237
Study 11720426 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated chemotherapy with EVI and GM-CSF support (Arm B)
Number of subjects: 233
Study 11720426 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy with EVI (Arm A)
Number of subjects: 233
Study 11720426 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated chemotherapy with EVI and oral antibiotics (Arm C)
Number of subjects: 233
Study 9219909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil treatment
Number of subjects: 26
Study 9219909 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 26
Study 8238379 — intervention group
Group type: EXPERIMENTAL
Intervention: FK‐453 (100 mg)
Number of subjects: 8
Study 8238379 — intervention group
Group type: EXPERIMENTAL
Intervention: FK‐453 (200 mg)
Number of subjects: 8
Study 8238379 — intervention group
Group type: EXPERIMENTAL
Intervention: FK‐453
Number of subjects: 8
Study 8238379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3312331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate 0.5%
Number of subjects: 0
Study 3312331 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 0.25%
Number of subjects: 0
Study 3312331 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparsal
Number of subjects: 0
Study 3312331 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 28887752 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen 15 mg/kg/dose
Number of subjects: 400
Study 28887752 — intervention group
Group type: COMPARATOR
Intervention: PO acetaminophen 15 mg/kg/dose
Number of subjects: 400
Study 27265058 — intervention group
Group type: EXPERIMENTAL
Intervention: Text prediction functions
Number of subjects: 52
Study 27265058 — intervention group
Group type: COMPARATOR
Intervention: No text prediction functions (Control)
Number of subjects: 52
Study 25675169 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival local anesthesia with 2% lidocaine gel
Number of subjects: 120
Study 25675169 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous local anesthesia without topical anesthetic
Number of subjects: 120
Study 25675169 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival injection
Number of subjects: 120
Study 22305809 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (1000 mg orally before angioplasty and 500 mg twice daily for 3 days after intervention)
Number of subjects: 204
Study 22305809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probucol treatment)
Number of subjects: 204
Study 21967862 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Check‐up Tool (TCT) administered monthly
Number of subjects: 46
Study 21967862 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Check‐up Tool (TCT)
Number of subjects: 46
Study 21967862 — intervention group
Group type: EXPERIMENTAL
Intervention: CLABSI rate, Team Functioning Survey (TFS), Practice Environment Scale (PES) from the Nursing Work Index
Number of subjects: 46
Study 18807007 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced 6% HES 130/0.42 plus a balanced crystalloid solution
Number of subjects: 50
Study 18807007 — intervention group
Group type: COMPARATOR
Intervention: Non‐balanced HES in saline plus saline solution
Number of subjects: 50